Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.9 USD | -1.84% | +1.34% | +48.86% |
May. 03 | Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53 | MT |
May. 02 | Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
Financials (USD)
Sales 2024 * | 50.98M | Sales 2025 * | 67.75M | Capitalization | 2.33B |
---|---|---|---|---|---|
Net income 2024 * | -206M | Net income 2025 * | -240M | EV / Sales 2024 * | 38.2 x |
Net cash position 2024 * | 380M | Net cash position 2025 * | 373M | EV / Sales 2025 * | 28.8 x |
P/E ratio 2024 * |
-13.1
x | P/E ratio 2025 * |
-11.6
x | Employees | 186 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.75% |
Latest transcript on Kymera Therapeutics, Inc.
1 day | -1.84% | ||
1 week | +1.34% | ||
Current month | +12.73% | ||
1 month | +7.27% | ||
3 months | +1.85% | ||
6 months | +161.02% | ||
Current year | +48.86% |
Managers | Title | Age | Since |
---|---|---|---|
Nello Mainolfi
FOU | Founder | 45 | 15-08-31 |
Bruce Jacobs
DFI | Director of Finance/CFO | 54 | 19-07-14 |
Juliet Williams
CTO | Chief Tech/Sci/R&D Officer | - | 21-05-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | Mar. 27 |
Joanna Horobin
BRD | Director/Board Member | 69 | 18-04-30 |
John Maraganore
BRD | Director/Board Member | 60 | 22-01-16 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 0 M€ | 0.00% | - | |
0.09% | 0 M€ | 0.00% | - | |
0.04% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 37.9 | -1.84% | 333,731 |
24-05-09 | 38.61 | +0.29% | 450,442 |
24-05-08 | 38.5 | +0.16% | 453,270 |
24-05-07 | 38.44 | +0.37% | 331,904 |
24-05-06 | 38.3 | +2.41% | 426,797 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.86% | 2.33B | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- KYMR Stock